Bridget P. Belcher

I'll research this attorney's background and practice.

Let me verify the tracked cases and her PTAB work.

Let me pin down a few specifics.

Bridget P. Belcher, Ph.D. — Patent Agent, Desmarais LLP (San Francisco)

Note on credential: Public records identify Ms. Belcher as a registered patent agent (USPTO Reg. No. 82,861), not a licensed attorney. Her firm bio and the PTAB filings reviewed list her as "Patent Agent," and no state bar admission was found. The docketed "attorney" label in the tracked data should be read as practitioner-of-record, not bar membership.

Specialty / focus. Her practice is chemistry- and life-sciences-centered. Desmarais's bio describes her work as "review and evaluation of technology in the fields of chemistry, biotechnology, pharmaceuticals, and medical devices," and her doctoral research at UC Berkeley (Nomura Lab) concerned chemoproteomic profiling of covalent anti-cancer natural products, photoaffinity probe design, and E3 ligase ligandability in targeted protein degradation. The two tracked matters are consistent with that profile: pharmaceutical/photodynamic-therapy patents (Sun Pharmaceutical v. Biofrontera Bioscience) and materials-science/semiconductor fabrication patents (Samsung v. Chien-Min Sung, involving chemical-mechanical polishing pad dressers). So while the chemistry/pharma core is well supported, at least one matter sits in the mechanical/materials-and-semiconductor-process space rather than pharma.

Side preference. Both tracked appearances are on the asserting/plaintiff-petitioner side (2 plaintiff, 0 defendant), and Desmarais is a patent-owner/plaintiff-oriented IP trial boutique. That said, the sample is very small (two matters) and she appears in at least one IPR as back-up counsel for a patent owner, so a strict "always petitioner" characterization isn't warranted.

Firm context. Desmarais LLP, San Francisco office. No prior law-firm employment was found; her pre-Desmarais experience is academic research (UC Berkeley 2019–2023; Stonehill College; an MIT Amgen Scholars placement at the Koch Institute). She joined Desmarais after her 2023 Ph.D.

Notable matters. In the Sun Pharmaceutical / Biofrontera dispute over photodynamic-therapy patents (U.S. Pat. Nos. 11,446,512 and 11,697,028), the firm won an ITC final determination of infringement and obtained limited exclusion and cease-and-desist orders (Inv. No. 337-TA-1411), while Biofrontera's parallel IPRs produced a Feb. 2026 final written decision holding the '028 claims unpatentable and a denial of institution on the '512 petition on procedural grounds. On the Samsung side, the PTAB invalidated the asserted CMP pad-dresser patents, and the E.D. Tex. case (Sung v. Samsung, No. 4:23-cv-00752) was resolved by settlement and dismissal (reported March 2026). Both outcomes cut against the client-side posture she appeared for depending on the forum. She is also listed among the Desmarais trial team that obtained a $20.2 million jury verdict for Harbour in an antibody patent trial (firm announcement), though her role was not a lead one.

PTAB / IPR. Yes — she appears in PTAB proceedings, including as designated back-up counsel for a patent owner in a 2025 IPR (per an updated mandatory notice adding her as back-up counsel effective July 1, 2025) and on Samsung's IPR team against Sung. Her PTAB work is in a supporting technical/counsel capacity rather than as lead counsel, which is typical for a patent agent.

Bar / education. Registered to practice before the USPTO (Reg. No. 82,861); Ph.D., Chemistry, UC Berkeley, 2023; B.S., Chemistry, Stonehill College, 2019 (summa cum laude). No state bar admission identified.

Sourcing note: the education, registration number, and practice description come from her Desmarais profile and PTAB filings; case outcomes come from firm announcements, PTAB/docket records, and press reporting. Her precise role in each matter (technical support vs. examination of witnesses, etc.) is not publicly detailed.